Saturday, October 31, 2026

Markets & Investing

3 articles

Activist Fund 3D Investment Partners Forces Public Showdown at Toho HD's 78th AGM

Activist Fund 3D Investment Partners Forces Public Showdown at Toho HD's 78th AGM

U.S.-based 3D Investment Partners has escalated its multi-year campaign against Japanese conglomerate Toho HD into full public confrontation days before the company's 78th annual general meeting. The fund deployed a white paper, manga-format shareholder letters, and a dedicated campaign website after Toho HD's board installed a poison pill without a shareholder vote. The battle mirrors earlier proxy fights at Toshiba and Seven & i that forced major corporate restructuring.

LM Salvado•
Global Investors Hold Hidden AI Bet Inside World's Largest ETF

Global Investors Hold Hidden AI Bet Inside World's Largest ETF

Vanguard's VOO ETF approached $1 trillion in assets after $100 billion in 2025 inflows, but 34% of the fund sits in information technology. Four AI infrastructure companies — Nvidia, Microsoft, Alphabet, and Amazon — drive the fund's returns, exposing investors worldwide to concentrated AI capex risk. Most buyers treat VOO as broad diversification; they are effectively holding a leveraged position on sustained hyperscaler spending.

LM Salvado•
Copa Holdings and the Single-Hub Trap: A Global Warning for Concentrated Aviation Networks

Copa Holdings and the Single-Hub Trap: A Global Warning for Concentrated Aviation Networks

Copa Holdings has built one of the most efficient airline hub models in the world, routing the vast majority of its Latin American traffic through a single airport in Panama. But as global aviation analysts increasingly scrutinize network concentration risk, Copa's Tocumen dependency stands as a case study in the structural vulnerabilities that efficiency-first strategies can create. The stakes extend beyond one airline — they reflect a broader tension between operational elegance and systemic r

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com